Galderma Group AG (GALD) Price & Analysis

Compare

10 Followers

GALD Stock Chart & Stats

CHF148.00

-CHF8.02(-7.15%)

At close: Mar 06 4:00 PM EST

CHF148.00

-CHF8.02(-7.15%)

Day’s Range― - ―

52-Week RangeCHF72.70 - CHF153.30

Previous CloseN/A

Volume230.69K

Average Volume (3M)337.59K

Market Cap

CHF34.75B

Enterprise ValueCHF29.23B

Total Cash (Recent Filing)CHF458.00M

Total Debt (Recent Filing)CHF2.85B

Price to Earnings (P/E)107.1

Beta0.87

Next Earnings

Mar 05, 2026

EPS Estimate

1.19

Last Dividend Ex-Date

Apr 25, 2025

Dividend Yield0.1%

Share Statistics

EPS (TTM)1.12

Shares Outstanding237,897,630

10 Day Avg. Volume210,266

30 Day Avg. Volume337,589

Financial Highlights & Ratios

PEG Ratio-0.21

Price to Book (P/B)3.38

Price to Sales (P/S)5.93

P/FCF Ratio123.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF158.00

Price Target Upside6.76% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceMargin expansion will be progressive, indicating a positive outlook for the company's profitability.

Product Launch SuccessGalderma has seen a 'phenomenal' initial launch of Sculptra, with potential for the biostimulator category to become a leading component of the market.

Sales GrowthGalderma Group AG's third-quarter sales grew by 21%, outperforming consensus expectations by 4%.

Bears Say

Impact Of HolidaysThe US Labor Day holiday adversely impacted new patient starts, affecting prescription volumes.

Market VolatilitySensitivity to forecasts still lies around net realized pricing, indicating potential volatility.

Trade Tariff UncertaintyTrump announced the intention to impose a 100% tariff on imports of branded or patented drugs, adding uncertainty to the market.

Galderma Group AG News

Galderma Group AG: Promising Growth Potential and Strategic Market Positioning Drive Buy Rating

Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG and keeping the price...

11d ago

Galderma Group AG: Strong Q3 Performance Amid Market Challenges, Hold Rating Reflects Balanced Outlook

Analyst Thibault Boutherin from Morgan Stanley maintained a Hold rating on Galderma Group AG and keeping the price...

16d ago

Galderma Group AG: Strong Q3 Performance and Growth Potential Justify Buy Rating

Galderma Group AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin Jackson...

16d ago

Galderma Group AG: Buy Rating Affirmed Amid Tariff Challenges and Growth Prospects

Benjamin Jackson CFA, an analyst from Jefferies, maintained the Buy rating on Galderma Group AG. The associated price...

1M ago

Strong Buy Rating for Galderma Group AG Driven by Nemluvio’s Market Performance and Medical Relevance

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG,...

2M ago

Galderma Group AG: Strong First Half Performance and Upgraded Sales Outlook Justify Buy Rating

Jefferies analyst Benjamin Jackson CFA maintained a Buy rating on Galderma Group AG today and set a price...

4M ago

Positive Outlook for Galderma Group AG Driven by Strong Nemluvio Prescription Growth and Upbeat Sales Forecast

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG,...

4M ago

Strong Growth Prospects for Galderma Group AG Driven by Nemluvio’s Performance

Jefferies analyst Lucy Codrington has maintained their bullish stance on GALD stock, giving a Buy rating on July...

4M ago

Strong Market Performance and Growth Potential Drive Buy Rating for Galderma Group AG

Benjamin Jackson CFA, an analyst from Jefferies, maintained the Buy rating on Galderma Group AG (GALD – Research...

4M ago

Strong Future Prospects for Galderma Group AG: Buy Rating Supported by Product Uptake and Market Expansion Opportunities

Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG (GALD – Research Report)...

5M ago

GALD FAQ

What was Galderma Group AG’s price range in the past 12 months?

Galderma Group AG lowest stock price was CHF72.70 and its highest was CHF153.30 in the past 12 months.

What is Galderma Group AG’s market cap?

Galderma Group AG’s market cap is CHF34.75B.

When is Galderma Group AG’s upcoming earnings report date?

Galderma Group AG’s upcoming earnings report date is Mar 05, 2026 which is in 117 days.

How were Galderma Group AG’s earnings last quarter?

Galderma Group AG released its earnings results on Jul 24, 2025. The company reported CHF1.124 earnings per share for the quarter, beating the consensus estimate of CHF0.942 by CHF0.182.

Is Galderma Group AG overvalued?

According to Wall Street analysts Galderma Group AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Galderma Group AG pay dividends?

Galderma Group AG pays a Notavailable dividend of CHF0.15 which represents an annual dividend yield of 0.1%. See more information on Galderma Group AG dividends here

What is Galderma Group AG’s EPS estimate?

Galderma Group AG’s EPS estimate is 1.19.

How many shares outstanding does Galderma Group AG have?

Galderma Group AG has 237,897,630 shares outstanding.

What happened to Galderma Group AG’s price movement after its last earnings report?

Galderma Group AG reported an EPS of CHF1.124 in its last earnings report, beating expectations of CHF0.942. Following the earnings report the stock price went up 7.575%.

Which hedge fund is a major shareholder of Galderma Group AG?

Currently, no hedge funds are holding shares in CH:GALD

Company Description

Galderma Group AG

Galderma Group AG is a global dermatology company headquartered in Switzerland, specializing in the development and commercialization of innovative medical solutions for skin health. The company operates primarily in the fields of medical dermatology, aesthetic dermatology, and consumer skin care. Galderma's core products include prescription medications for various skin conditions, aesthetic treatments such as dermal fillers and botulinum toxin, and a range of over-the-counter skin care products designed to address diverse skin concerns.

Galderma Group AG (GALD) Earnings & Revenues

Historic Earnings Reports

GALD Stock 12 Month Forecast

Average Price Target

CHF158.00

▲(6.76% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"CHF88","183":"CHF183","111.75":"CHF111.8","135.5":"CHF135.5","159.25":"CHF159.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF182.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":158,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF158.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF135.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,111.75,135.5,159.25,183],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,148.5,151.07692307692307,153.65384615384616,156.23076923076923,158.80769230769232,161.3846153846154,163.96153846153845,166.53846153846155,169.1153846153846,171.69230769230768,174.26923076923077,176.84615384615384,179.42307692307693,{"y":182,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,148.5,149.23076923076923,149.96153846153845,150.69230769230768,151.42307692307693,152.15384615384616,152.8846153846154,153.6153846153846,154.34615384615384,155.07692307692307,155.80769230769232,156.53846153846155,157.26923076923077,{"y":158,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,148.5,147.46153846153845,146.42307692307693,145.3846153846154,144.34615384615384,143.30769230769232,142.26923076923077,141.23076923076923,140.19230769230768,139.15384615384616,138.1153846153846,137.07692307692307,136.03846153846155,{"y":135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":89.41,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":100.47,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":100.47,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.52,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >